Schering PEG-Intron Phase IV Trial To Study African Americans

Schering-Plough will study whether the hepatitis C treatment PEG-Intron produces lower response rates in African American patients following approval of the pegylated interferon.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet